We are happy to be able to present to you our new homepage. Our Internet presence in a new design is now more clearly structured and offers interested consumers, customers and partners comprehensive information about our company and products.
Featured is on our Online Shop, where you can easily order our products. We welcome praise and criticism.
Immunservice has just finalized work to establish a Webshop offering specialty products primarily for use in functional diagnostics (cell proliferation, bioassay, interleukin-2 activity, etc.). An important benefit is that all products are developed even in a stress test and optimized in a labour-intensive process for special applications.
Offered for cell culture of special cells are complete, ready-to-use media with long-term stability and formulated specifically for growth of interleukin-2 dependent cells. There is a special ready-to-use CTLL-2 medium in which these fastidious cells absolutely thrive. This proliferation can be visualized in colour and measured using WST modified specifically for CTLL-2 cells.
“We offer thoroughly tested specialty products that scientists otherwise have to mix and test themselves in a time-consuming process. This is unique and saves researchers time and leaves more room for their actual research. And those wanting to completely outsource function and proliferation tests will find top quality support at our company,” commented Immunservice.
Immunservice is currently very successfully developing an innovative immunostimulant for subsequent use in papillomavirus-induced tumours in humans and – through our partner company 4Animals Alsterscience – also in animals.
Following a very positive interim analysis of immunological toxicology studies, today a nationwide study in Germany began in horses with so-called “sarcoids”, locally aggressive tumours that are triggered by papillomaviruses and very difficult to treat.
“The results of immunological studies in horses done so far are very promising, not just for animals but also for humans, where the virus can trigger cervical cancer and very difficult to treat tumours in mucous membranes,” said Prof. Huland, CEO of Immunservice.
Our offices are now conveniently located close to our laboratories in the immediate vicinity of the University Hospital Eppendorf. We’re saying goodbye to Neue Wall and looking forward to the new rooms at Christoph-Probst-Weg 4, 20251 Hamburg.
Immunservice has developed an innovative immunotherapy for obesity and nicotine addiction and been granted a US patent for this discovery. The results of clinical studies by Immunservice scientists clearly indicate it is possible to make therapeutic use of the influence of immune hormones to make people want to eat light and healthy food and adopt a healthier lifestyle with no extra effort necessary. Moreover, immune hormones apparently induce a natural lack of interest in nicotine consumption.
The discoveries by Immunservice GmbH offer new possibilities in the future to support people who want to lose weight or stick to resolutions to stop smoking. Patents have also been authorised in the European countries.
Immunservice GmbH has concluded a new round of financing (Series C) to secure development of the company’s biological immunotherapy methods for the long term. Joining the existing consortium of investors comprised of Helmut Piñata, the Hubertus-Wald-Sifting, the High-Tech-Gründerfonds (HTGF) and Hartwig Huland in the latest successful financing round was Dr. Michael Otto, entrepreneur and Chairman of the Board at the Otto Group.